The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID) (NIH)

Overall Status

Completed

CT.gov ID

NCT00000861

Collaborator

(none)

1,900

Enrollment

Locations

135.7

Patients Per Site

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effect of immediate versus deferred indinavir (IDV) in addition to background therapy on disease progression or death in patients with CD4+ cell counts between 200 and 500 cells/mm3 and plasma HIV RNA levels >= 10,000 copies/ml.

This study aims to examine two management strategies, immediate versus deferred IDV therapy, for their clinical effects in the context of background antiretroviral (AR) therapy, given according to current clinical practice. There is an urgent need to identify the optimal use of IDV in patient management, since clinical endpoint studies have not been completed in the United States. Since there is little information about the long term durability of clinical effects, and even less information about the timing of the initiation of protease inhibitor therapy, exploring the disease progression and survival impact of immediate versus delayed use of IDV will yield important information to guide clinical decision making for this group of patients.

Condition or Disease	Intervention/Treatment	Phase
HIV Infections	Drug: Indinavir sulfate	N/A

Detailed Description

Prior to randomization the patient and clinician will determine whether the background therapy will be zidovudine (ZDV) plus lamivudine (3TC) or other background antiretroviral therapy (OBAT). Patients will then be randomized to IDV or matching placebo. AS PER AMENDMENT 06/27/97: The protocol was closed as of 03/25/97, and all patients have been unblinded to their assigned treatment. Patients still on study medication are eligible for the protocol extension. Patients who were randomized to immediate IDV may continue on therapy for up to an additional 4 months. All study therapy, both for those on immediate or delayed therapy, must be discontinued on 10/24/97.

Study Design

Study Type:

Interventional

Masking:

Double

Primary Purpose:

Treatment

Official Title:

A Randomized Trial of Immediate Versus Deferred Indinavir in Addition to Background Antiretroviral Therapy in HIV-Infected Patients With CD4+ Cell Counts Between 200 and 500/mm3 and Plasma HIV RNA Levels >= 10,000 Copies/ml

Actual Study Completion Date :

Mar 1, 1997

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

16 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria

Concurrent Medication:

Allowed:

Topical and/or antifungal agents, except ketoconazole.
Treatment, maintenance, or chemoprophylaxis with approved agents for OIs will be given as clinically indicated.
Clinically indicated antibiotics, unless excluded.
Systemic corticosteroid use for <21 days for acute problems is permitted as clinically indicated. However, chronic systemic corticosteroid use should be avoided.
Recombinant erythropoietin (rEPO) and granulocyte-colony stimulating factor (G-CSF, filgrastim).
Didanosine (ddI).
Regularly prescribed medications, such as antipyretics, antidepressants, oral contraceptives, megestrol acetate, testosterone, or any other medication.

Patients must have:

A working diagnosis of HIV infection.
A CD4+ count between 200 and 500 cells/mm3.
Signed, informed parental consent if patient is less than 18.

NOTE:

The DAIDS Clinical Science Research Committee (CSRC) has deemed this protocol appropriate for prisoner enrollment.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following conditions or symptoms are excluded:

Febrile illness with temperature > 38.5 degrees C (101.3 degrees F) within 3 days prior to study entry.

Concurrent Medication:

Excluded:

Non-nucleoside reverse transcriptase inhibitors.
Protease inhibitors except IDV.
Rifabutin and rifampin.
Ketoconazole.
Terfenadine, astemizole, cisapride, triazolam and midazolam.

Patients with any of the following prior conditions are excluded:

History of prior saquinavir (SQV) therapy for more than 14 days.
History of any prior protease inhibitor therapy other than SQV.
History of serious opportunistic infection.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Community Consortium of San Francisco	San Francisco	California	United States	94110
2	Denver CPCRA / Denver Public Hlth	Denver	Colorado	United States	802044507
3	Veterans Administration Med Ctr / Regional AIDS Program	Washington	District of Columbia	United States	20422
4	AIDS Research Consortium of Atlanta	Atlanta	Georgia	United States	30308
5	AIDS Research Alliance - Chicago	Chicago	Illinois	United States	60657
6	Louisiana Comm AIDS Rsch Prog / Tulane Univ Med	New Orleans	Louisiana	United States	70112
7	Comprehensive AIDS Alliance of Detroit	Detroit	Michigan	United States	48201
8	Henry Ford Hosp	Detroit	Michigan	United States	48202
9	Southern New Jersey AIDS Cln Trials / Dept of Med	Camden	New Jersey	United States	08103
10	North Jersey Community Research Initiative	Newark	New Jersey	United States	071032842
11	Harlem AIDS Treatment Group / Harlem Hosp Ctr	New York	New York	United States	10037
12	Portland Veterans Adm Med Ctr / Rsch & Education Grp	Portland	Oregon	United States	972109951
13	Philadelphia FIGHT	Philadelphia	Pennsylvania	United States	19107
14	Richmond AIDS Consortium	Richmond	Virginia	United States	23298